Since President Trump announced his plan last month to lower prescription drug prices, a lot of rumors have been flying around that cuts are coming from certain companies, such as those that make insulin for diabetes patients. Those rumors haven’t materialized into anything real yet, but they did heighten the anticipation for today’s testimony from Health and Human Services (HHS) Secretary Alex Azar (pictured) before the Senate Health committee.
Unfortunately, any additional details from Trump’s “blueprint” to cut prices remained scant. Most of Azar’s testimony on Tuesday was spent explaining and defending the blueprint, which put forward a few… Read more »
UNDERWRITERS AND PARTNERS